Alaunos Therapeutics, Inc. (TCRT)
- Previous Close
3.0100 - Open
2.9500 - Bid 2.4400 x 100
- Ask 3.2500 x 100
- Day's Range
2.8100 - 3.0600 - 52 Week Range
1.3100 - 14.2000 - Volume
15,727 - Avg. Volume
489,345 - Market Cap (intraday)
4.673M - Beta (5Y Monthly) -1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-2.9200 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
www.alaunos.comRecent News: TCRT
View MorePerformance Overview: TCRT
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TCRT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCRT
View MoreValuation Measures
Market Cap
4.67M
Enterprise Value
-1.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
456.36
Price/Book (mrq)
2.26
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.59%
Return on Equity (ttm)
-111.80%
Revenue (ttm)
10k
Net Income Avi to Common (ttm)
-4.68M
Diluted EPS (ttm)
-2.9200
Balance Sheet and Cash Flow
Total Cash (mrq)
1.09M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.3M